For people living with advanced liver disease, the illness affects much more than the liver itself. One of the most serious complications is the gradual loss of muscle mass and strength, a condition known as sarcopenia.
This problem can make everyday activities difficult, increase the risk of falls, and worsen overall health outcomes. Patients who develop sarcopenia are more likely to experience infections and other complications, and their risk of death is significantly higher.
Although doctors have known about this problem for many years, they have struggled to understand exactly why it happens. As a result, treatment options remain limited, and no approved medications currently exist to specifically treat muscle loss in people with end-stage liver disease.
Researchers at the University of Birmingham have now uncovered evidence that may change how scientists think about the condition.
Their study, published in the Journal of Cachexia, Sarcopenia and Muscle, suggests that muscle loss does not develop in the same way in every patient. Instead, the biological processes involved appear to depend heavily on the type of liver disease a person has.
The discovery could eventually help doctors develop more personalized treatments that target the specific causes of muscle loss in individual patients.
The study involved examining muscle tissue from people with severe liver disease and comparing it with muscle samples from healthy individuals. The researchers used advanced genetic analysis to investigate which genes were active inside the muscle cells.
Genes act as instructions that control how cells function. By examining patterns of gene activity, scientists can gain valuable insights into the biological changes occurring within tissues. The researchers found that more than 600 genes behaved differently in muscle tissue from patients with liver disease.
Many of these genetic changes affected important functions such as how cells generate energy, how proteins are built and broken down, and how cells respond to stress and aging. These processes are all closely linked to muscle growth and maintenance.
What surprised the researchers was how different the results looked when patients were grouped according to the cause of their liver disease. People with alcohol-related liver disease showed one pattern of changes. Those with metabolic liver disease showed another. Patients with immune-associated liver disease displayed yet another distinct pattern.
These findings suggest that sarcopenia is not a single disease but rather a collection of related conditions with different underlying causes.
To investigate further, the researchers examined blood samples from the patients. Blood contains many signaling molecules that help different parts of the body communicate with each other. Some of these signals can influence muscle growth and repair.
The team measured 60 different proteins involved in inflammation, growth regulation, and tissue repair. They then exposed human muscle cells grown in the laboratory to blood plasma from patients with liver disease.
The results were striking. The plasma triggered changes in the muscle cells that closely resembled those seen in patient tissue. The cells became smaller, showed reduced growth, and increased the breakdown of proteins. These are all hallmarks of muscle wasting.
Three proteins emerged as particularly important. These were IL-1α, GDF-15, and HGF. Each appeared to be associated with different forms of liver disease.
GDF-15 was elevated across all patient groups, suggesting it may play a central role in muscle loss regardless of the underlying disease. IL-1α was mainly associated with immune-related liver disease, while HGF was more strongly linked to metabolic and alcohol-related liver disease.
The researchers then tested the effects of these proteins directly on healthy muscle cells. The proteins caused the cells to become thinner and disrupted their ability to produce energy efficiently. These findings provide strong evidence that the proteins contribute directly to muscle wasting.
The study is particularly encouraging because some drugs already in use or under development target these proteins. This creates the possibility that existing medications could be adapted to help protect muscle health in people with liver disease.
Researchers believe future treatments may combine drug therapy with exercise programs and nutritional support. Rather than giving every patient the same treatment, doctors may eventually be able to identify the biological drivers of muscle loss in each person and select therapies accordingly.
The findings represent an important step toward precision medicine for liver disease patients. One strength of the study is its detailed analysis of both muscle tissue and blood samples from real patients.
However, more clinical research will be needed before new treatments become available. The results provide strong evidence that understanding the specific cause of liver disease may be essential for developing effective strategies to prevent or reverse muscle loss in the future.
If you care about liver health, please read studies about simple habit that could give you a healthy liver, and common diabetes drug that may reverse liver inflammation.
For more information about health, please see recent studies about simple blood test that could detect your risk of fatty liver disease, and results showing this green diet may strongly lower non-alcoholic fatty liver disease.
Source: University of Birmingham.
